Revolution Medicines Inc. has synthesized macrocyclic compounds acting as GTPase KRAS, NRAS, HRAS and their mutant inhibitors reported to be useful for the treatment of cancer.
Samjin Pharmaceutical Co. Ltd. has disclosed nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer.
Gait instability and somnolence are the main hindbrain-related adverse effects associated with the inhibition of AMPA receptors (AMPARs). Transmembrane AMPAR regulatory proteins (TARPs) modulate AMPAR function, with the specific member TARPγ8 being highly expressed in brain regions associated with seizures and expressed at low or negligible levels in the hindbrain.
Researchers from Arvinas Inc. reported the preclinical characterization of bavdegalutamide (ARV-110), an androgen receptor (AR)-directed proteolysis targeting chimera (PROTAC) designed to selectively degrade wild-type AR and the majority of clinically relevant mutants of AR.
The milestone is for the identification of candidates meeting the predefined lead compound criteria, and follows the initial milestone achieved in December 2023.
Kaken Pharmaceutical Co. Ltd. and Johnson & Johnson (J&J) have entered into a license agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), developed by Kaken.
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now seven approved GLP-1RAs. Commercially, the most successful one so far is semaglutide, sold under the brand name Wegovy or Ozempic depending on the indication.
RSS
